# TRITON2 (NCT02952534)

> A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02952534
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: pharmaand GmbH
- Conditions: Metastatic Castration Resistant Prostate Cancer
- Interventions: Rucaparib
- Enrollment: 277
- Primary outcome: Confirmed Objective Response Rate (ORR) by Gene in Patients With Measurable Disease at Baseline Per Central Independent Radiology Review (IRR)

## Commentary we found

- Podcasts: 27
- YouTube: 14
- X threads: 9

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=triton2-nct02952534

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02952534", "email": "<work email>"}; the inbox owner confirms by the emailed link.